Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib

Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the liter...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravbrot, Nicholas, Sundararajan, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800898/
https://www.ncbi.nlm.nih.gov/pubmed/31687241
http://dx.doi.org/10.1155/2019/3051945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800898/
https://www.ncbi.nlm.nih.gov/pubmed/31687241
http://dx.doi.org/10.1155/2019/3051945

Ejemplares similares